Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congress backs CDRH raise

This article was originally published in The Gray Sheet

Executive Summary

Senate votes 93-1 to spend $209.3 mil. for device center in FY 2004 agriculture approps bill Nov. 6, including $29.2 mil. in user fees. The House-cleared report offers $193.5 mil. in CDRH budget authority, while the Senate report originally proposed $191.9 mil. (1"The Gray Sheet" Nov. 3, 2003, p. 5). In its request to reconcile the amounts, the Senate appointed 17 conferees...

You may also be interested in...



Omnibus appropriations

Senate may reconvene in December to consider seven-bill spending package, which would dole out $209.4 mil. for CDRH in agriculture appropriations conference report provision. The House is scheduled to consider the legislation when it reconvenes during the week of Dec. 8; Senate options include funding FDA at FY 2003 levels under a continuing resolution through Jan. 31, 2004, or unanimous consent passage before year-end. The amount closely aligns with the Senate bill, passed Nov. 6 (1"The Gray Sheet" Nov. 10, 2003, In Brief)...

OMB’s FY 2005 Device Funding Request Leaves Industry Wary Of FDA Estimate

Legislative changes to the compensating adjustment factor affecting device user fee rates in fiscal 2005 and beyond could be accomplished if Congress revisits the MDUFMA "triggers" in 2004

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

UsernamePublicRestriction

Register

MT019286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel